Similar articles

• The role of cytotoxic therapy with hematopoietic stem cell transplantation in the therapy of myelodysplastic syndromes: an evidence-based review.

  Oliansky DM, Antin JH, Bennett JM, Deeg HJ, Engelhardt C, Heptinstall KV, de Lima M, Gore SD, Potts RG, Silverman LR, Jones RB, McCarthy PL Jr, Hahn T. Oliansky DM, et al. Biol Blood Marrow Transplant. 2009 Feb;15(2):137-72. doi: 10.1016/j.bbmt.2008.12.003. Biol Blood Marrow Transplant. 2009. PMID: 19167676 Review.
• Hematopoietic stem cell transplantation for myelodysplastic syndrome.

  Parmar S, de Lima M. Parmar S, et al. Biol Blood Marrow Transplant. 2010 Jan;16(1 Suppl):S37-44. doi: 10.1016/j.bbmt.2009.10.018. Epub 2009 Oct 24. Biol Blood Marrow Transplant. 2010. PMID: 19857589 Review.
• Myelodysplastic syndromes: recent advances.

  Alessandrino EP, Amadori S, Cazzola M, Locatelli F, Mecucci C, Morra E, Saglio G, Visani G, Tura S. Alessandrino EP, et al. Haematologica. 2001 Nov;86(11):1124-57. Haematologica. 2001. PMID: 11694400 Review. No abstract available.
• Myelodysplastic syndromes clinical practice guidelines in oncology.

  Greenberg PL, Baer MR, Bennett JM, Bloomfield CD, De Castro CM, Deeg HJ, Devetten MP, Emanuel PD, Erba HP, Estey E, Foran J, Gore SD, Millenson M, Navarro WH, Nimer SD, O'Donnell MR, Saba HI, Spiers K, Stone RM, Tallman MS. Greenberg PL, et al. J Natl Compr Canc Netw. 2006 Jan;4(1):58-77. J Natl Compr Canc Netw. 2006. PMID: 16403405 No abstract available.
• Emerging therapeutic strategies for myelodysplastic syndrome.

  Barrett J, Battiwalla M. Barrett J, et al. Curr Hematol Rep. 2003 May;2(3):193-201. Curr Hematol Rep. 2003. PMID: 12901340 Review.